Osimertinib is now approved as a second line treatment after acquired resistance to earlier EGFR-TKIs due to the T790 mutation, and as a first line treatment for NSCLC patients with the common activated EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.